Novo Nordisk A/S (NVO) Stock Valuation: P/E Ratio and Intrinsic Value

Is Novo Nordisk A/S stock expensive or cheap? This page shows the price-earnings ratio of Novo Nordisk A/S for the last fiscal years, the current share price, and beta and volatility as risk measures. Earnings figures come from the company's published filings (FY 2025).

Earnings basis for the valuation (FY 2025)

Revenue309.06 DKK bn
Net income102.43 DKK bn
Net margin33.1 %

How the Novo Nordisk A/S P/E ratio is calculated

The price-earnings ratio divides the share price by earnings per share. On this page the ratio is shown per fiscal year, so you can see whether today's valuation of Novo Nordisk A/S is above or below its own history. Beta and volatility indicate how strongly the share moves compared with the overall market.

Frequently asked questions about Novo Nordisk A/S

What is the NVO P/E ratio?

The P/E ratio divides the Novo Nordisk A/S share price by earnings per share. This page shows the ratio for each of the last fiscal years, so the current valuation of NVO can be compared with its own history.

Is Novo Nordisk A/S stock overvalued or undervalued?

There is no single answer. A useful check is whether the current P/E of NVO is above or below its multi-year average and how earnings, margins and revenue are developing. This page shows all of these figures from the published filings.

How can I estimate the intrinsic value of Novo Nordisk A/S?

An intrinsic value estimate needs earnings or free cash flow, a growth assumption and a discount rate. This page provides the reported earnings basis, margins and the valuation history of NVO as the starting point.

More on Novo Nordisk A/S